Table 4 Association of TSR with other clinicopathological factors

All patients

400 (100)

3.3 (2.0–5.3)

Age

 <55

56 (14)

3.0 (1.8–4.0)^a

0.019

 55–64

125 (31)

3.4 (2.0–5.3)^a,b

 65–74

134 (34)

3.0 (1.9–5.4)^a,b

 ≥75

85 (21)

4.7 (2.5–6.0)^b

Stage (FIGO 2009)

 I

230 (58)

3.0 (1.8–4.9)

0.192

 II

71 (18)

4.0 (2.5–6.6)

 III

75 (19)

3.6 (2.1–5.3)

 IV

24 (6)

4.8 (2.6–6.2)

Grade

 1

149 (37)

2.8 (1.7–4.8)^a

<0.001

 2

106 (27)

3.2 (1.9–4.9)^a,b

 3

145 (36)

4.1 (2.3–6.0)^b

Histology

 Endometrioid (EEC)

302 (75.5)

3.2 (2.0–5.1)

1.000

 Non–EEC

48 (12)

3.9 (2.2–6.6)

 Mixed EEC/non-EEC

50 (12.5)

3.3 (1.9–5.4)

Depth of myometrial invasion

 Inner half

210 (52.5)

3.1 (1.7–5.6)

1.000

 Outer half

190 (47.5)

3.6 (2.2–5.0)

Cervical involvement

 No

261 (65)

3.0 (1.7–5.0)

0.108

 Yes

128 (32)

3.7 (2.3–5.4)

 Missing data

11 (3)

-

Lymph nodes positive

 No

274 (68.5)

3.3 (2.0–5.3)

1.000

 Yes

50 (12.5)

3.8 (2.2–5.8)

 No lymphadenectomy

76 (19)

-

Lymphovascular invasion

 No

203 (51)

2.9 (1.6–4.8)

<0.001

 Yes

193 (48)

3.9 (2.2–5.8)

 Missing data

4 (1)

-

Adjuvant treatment

 No

240 (60)

3.2 (1.9–5.2)

1.000

 Yes

160 (40)

3.6 (2.1–5.4)